This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
.–( BUSINESS WIRE )– EdiGene, Inc. which developsgenome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of BusinessDevelopment. He received his B.S.
After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate BusinessDevelopment, Life Science and Healthcare. Avideh Nazeri is vice president clinicaldevelopment, medical, and regulatory affairs, Novo Nordisk UK.
According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need. Commenting on the announcement, Daniel Gruskin, M.D., LogicBio is headquartered in Lexington, Mass.
Taveras will lead all research and non-clinicaldevelopment functions supporting the company’s pipeline of investigational therapies. VectivBio AG – Based in Switzerland, VectivBio named Sarah Holland as chief business officer and Aditya Venugopal as head of businessdevelopment.
Barber’s work will give Kiromic a significant acceleration in the clinicaldevelopment of its therapy platform and an even more significant advantage over its competitors. Amorette Barber of Longwood University will be heading up our chPD1 program. “We believe Prof. Barber also serves on Kiromic’s Scientific Advisory Board.
Prior to Celgene, she held leadership roles in marketing, sales and new businessdevelopment from 2002 to 2011 at Johnson & Johnson. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Before that, Ms. About MultiStem ®.
The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic businessdevelopment prospects. Deerfield and Illumina win the Research and Development award this year due to their commitment to research into AI-driven therapies. Innovation.
Marianne De Backer, Head of BusinessDevelopment & Licensing in Bayer’s Pharmaceuticals Division, pictured above. As a result, the company settled on four areas of focus – iPSC, allogenic CAR-T, genome mutations and gene editing. Photo courtesy of Bayer. We have set the bar high.
Acuitas’ proprietary LNP technology is used in multiple vaccines and therapeutics in clinicaldevelopment and was also used in some of the COVID-19 vaccines that were approved and administered to people in 180 countries. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.
50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC).
The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content